car-t-cells

Documents about car-t-cells

• Long-term Follow-up Study of Patients Receiving CAR-T Cells#918878ClinicalTrials.gov
• Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients#908432ClinicalTrials.gov
• The 1000 + mouse project for largescale spatiotemporal parametrization and modeling of preclinical cancer immunotherapies#274263HAL (France)
• Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium#312070HAL (France)
• A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer#332745ClinicalTrials.gov
• Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors#460088ClinicalTrials.gov
• UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma#875952ClinicalTrials.gov
• Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children#886634ClinicalTrials.gov
• Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors#966316ClinicalTrials.gov
• Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases#903079ClinicalTrials.gov
• Phase 2 Study of Rapcabtagene Autoleucel in Myositis#827901ClinicalTrials.gov
• GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)#369834ClinicalTrials.gov
• A symposium update on the key perspectives in systemic sclerosis and systemic lupus erythematosus#448828HAL (France)
• Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma#643031HAL (France)
• Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma#830407ClinicalTrials.gov
• Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma#898441ClinicalTrials.gov
• Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)#888357ClinicalTrials.gov
• A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer#828228ClinicalTrials.gov
• PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer#140987ClinicalTrials.gov
• NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma#349970ClinicalTrials.gov
• HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma#363619ClinicalTrials.gov
• Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease#414505ClinicalTrials.gov
• Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease#851290ClinicalTrials.gov
• A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia#856671ClinicalTrials.gov
• A Phase I Dose Finding Study of MB-CART2219.1#858829ClinicalTrials.gov
• CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies#878848ClinicalTrials.gov
• Long-Term Follow-up Study for Patients Previously Treated With JCAR015#880935ClinicalTrials.gov
• A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia#896249ClinicalTrials.gov
• Establishment of a scalable engineered cell-line platform for direct, GMP-grade production of eVLP vectors enabling streamlined generation of gene-edited CAR-T/NK cells.#446228NCBI PubMed Central
• Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases#867916ClinicalTrials.gov
• Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation#801495ClinicalTrials.gov
• Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma#121360ClinicalTrials.gov
• Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma#883306ClinicalTrials.gov
• Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia#125823ClinicalTrials.gov
• Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation#862796ClinicalTrials.gov
• Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells#181761ClinicalTrials.gov
• Targeted delivery of mRNA to immune cells for <i>in vivo</i> cell therapy#676323Europe PMC
• Transcriptional and functional profiling reveals unique activation of Adapter CAR T cells in acute myeloid leukemia / Nele Knelangen, Ulrika Bader, Evangelia Maniaki, Boris Engels, Luca Gattinoni, Jörg Mittelstät#784006Deutsche Nationalbibliothek
• Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas#885787ClinicalTrials.gov
• Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma#888742ClinicalTrials.gov
• CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children#911818ClinicalTrials.gov
• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia#801882ClinicalTrials.gov
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)#883085ClinicalTrials.gov
• A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer#801446ClinicalTrials.gov
• Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis#901469ClinicalTrials.gov
• T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia#851126ClinicalTrials.gov
• CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)#861685ClinicalTrials.gov
• Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma#230466ClinicalTrials.gov
• A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)#833406ClinicalTrials.gov
• Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL#884687ClinicalTrials.gov